China Pharma Holdings, Inc. (CPHI) Income Statement
CPHI 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsCPHI revenue and net income
Where CPHI's revenue goes
2025Each bar shows an amount and its share of revenue. CPHI kept −76.9% of revenue as net income.
CPHI profit margins
CPHI growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −8.5% | −20.0% | −17.5% | −14.7% |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
CPHI quarterly EPS vs estimates
China Pharma beat the analyst EPS estimate in 0 of the last 2 quarters. Next report: November 11, 2026.
CPHI income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.1M | $4.5M | $7.0M | $8.1M | $9.6M | $10.9M | $10.9M | $12.3M | $13.2M | $15.6M |
| Cost of revenue | $4.3M | $6.5M | $7.3M | $8.6M | $9.3M | $8.9M | $9.4M | $10.4M | $10.7M | $12.4M |
| Gross profit | −$131,950 | −$2.0M | −$281,085 | −$493,916 | $349,270 | $2.0M | $1.5M | $2.0M | $2.5M | $3.2M |
| Research & development | $280,901 | $283,942 | $240,080 | $185,858 | $318,964 | $377,964 | $229,637 | $172,384 | $90,474 | $365,969 |
| Sales, general & admin | $2.5M | $2.3M | $2.2M | $1.9M | $1.7M | $4.0M | $4.6M | $1.9M | $2.0M | $2.3M |
| Total operating expenses | $3.0M | $2.6M | $2.5M | $3.1M | $3.2M | $4.5M | $4.9M | −$12.4M | −$21.1M | −$11.4M |
| Operating income | −$3.1M | −$4.6M | −$2.8M | −$3.5M | −$2.9M | −$2.6M | −$3.4M | −$4.0M | −$4.5M | −$4.2M |
| Interest income | $2,003 | $6,641 | $5,075 | $10,755 | $3,035 | $5,675 | $27,527 | $38,516 | $64,414 | $130,575 |
| Interest expense | $102,037 | $154,140 | $333,600 | $434,619 | $542,000 | $294,159 | $321,718 | $451,258 | $539,334 | $849,557 |
| Income before taxes | −$3.2M | −$4.7M | −$3.1M | −$4.0M | −$3.4M | −$2.9M | −$20.7M | −$10.9M | −$19.2M | −$8.9M |
| Income taxes | — | −$4.74T | −$4 | $6.2M | $542,000 | $294,159 | $321,718 | −$109,989 | $122,631 | $308,175 |
| Net income | −$3.2M | −$4.7M | −$3.1M | −$4.0M | −$3.4M | −$2.9M | −$20.7M | −$10.8M | −$19.3M | −$9.2M |
| EBITDA | −$1.5M | −$2.0M | $8,435 | −$837,689 | $230,345 | $106,852 | −$17.5M | −$7.2M | −$15.3M | −$4.9M |
| EPS (diluted) | −$0.21 | −$2.80 | −$7.15 | −$0.26 | −$0.08 | −$0.09 | −$0.64 | −$0.39 | −$0.13 | $0.08 |
| Gross margin | −3.2% | −43.8% | −4.0% | −6.1% | 3.6% | 18.0% | 13.6% | 16.0% | 18.7% | 20.7% |
| Operating margin | −74.5% | −101.3% | −39.2% | −43.8% | −29.7% | −23.7% | −31.0% | −32.2% | −34.0% | −26.9% |
| Net margin | −76.9% | −104.6% | −43.9% | −49.0% | −35.3% | −26.4% | −189.5% | −87.2% | −145.9% | −59.0% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $948,340 | $983,536 | $1.2M | $756,217 | $1.0M | $1.1M | $1.1M | $1.1M | $924,943 | $1.4M | $2.1M | $1.8M |
| Cost of revenue | $864,774 | $1.5M | $1.1M | $815,871 | $1.1M | $1.3M | $1.2M | $1.6M | $2.0M | $1.7M | $2.2M | $2.0M |
| Gross profit | $83,566 | −$539,795 | $150,775 | −$59,654 | −$87,010 | −$136,061 | −$55,667 | −$519,649 | −$1.1M | −$290,024 | −$79,158 | −$233,190 |
| Research & development | $19,135 | $83,762 | $190,041 | $40,321 | $20,952 | $29,587 | $547 | $87,610 | $164,334 | $31,451 | $147,552 | $45,773 |
| Sales, general & admin | $1.5M | $1.1M | $1.2M | $502,868 | $542,126 | $594,293 | $1.0M | $479,654 | $91,870 | $596,643 | $949,337 | $246,267 |
| Total operating expenses | $1.5M | $577,469 | $2.4M | $568,491 | $565,110 | $1.9M | $1.1M | $565,608 | $271,213 | $626,028 | $3.3M | $480,352 |
| Operating income | −$1.4M | −$1.1M | −$1.2M | −$628,145 | −$652,120 | −$758,618 | −$1.2M | −$1.1M | −$1.4M | −$916,052 | −$1.2M | −$713,542 |
| Interest income | $81 | $147 | $213 | $294 | $422 | $1,074 | $1,335 | $1,460 | $1,531 | $2,315 | $2,530 | $2,182 |
| Interest expense | $26,359 | $26,031 | $22,604 | $24,046 | $27,359 | $28,028 | $29,731 | $34,114 | $48,140 | $42,155 | $50,252 | $66,240 |
| Income before taxes | −$1.5M | −$1.1M | −$1.2M | −$651,482 | −$528,367 | −$785,572 | −$1.2M | −$1.1M | −$1.4M | −$955,892 | −$1.2M | −$777,600 |
| Income taxes | — | — | — | — | — | — | $733,798 | −$1.12T | −$3 | $3 | — | −$683,094 |
| Net income | −$1.5M | −$1.1M | −$1.2M | −$651,482 | −$528,367 | −$785,572 | −$1.2M | −$1.1M | −$1.4M | −$955,892 | −$1.2M | −$777,600 |
| EBITDA | −$288,940 | −$136,547 | −$626,572 | −$271,402 | −$180,145 | — | −$746,628 | −$386,854 | −$650,738 | −$179,939 | — | −$28,266 |
| EPS (diluted) | −$0.04 | — | — | −$0.17 | −$0.16 | −$0.24 | −$0.53 | −$0.65 | −$0.89 | −$0.73 | −$1.16 | −$2.94 |
| Gross margin | 8.8% | −54.9% | 12.3% | −7.9% | −8.5% | −12.0% | −4.9% | −47.2% | −121.1% | −21.2% | −3.7% | −12.9% |
| Operating margin | −151.0% | −113.6% | −97.9% | −83.1% | −63.6% | −66.8% | −105.5% | −98.6% | −150.4% | −66.9% | −54.7% | −39.6% |
| Net margin | −153.8% | −116.2% | −99.7% | −86.2% | −51.5% | −69.1% | −108.0% | −101.6% | −155.5% | −69.8% | −57.3% | −43.1% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in CPHI's financial statements (latest annual report filed April 1, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
CPHI financial results
In fiscal year 2025 (ended December 31, 2025), China Pharma reported revenue of $4.1 million, down 8.5% from the year before. It had a net loss of $3.2 million, a net profit margin of −76.9%. Diluted earnings per share came to −$0.21. Over five years revenue grew at an average rate of −17.5% a year.
See the CPHI stock overview for the latest quote and news, or the CPHI chart for price history and technical indicators.
CPHI income statement FAQ
What is China Pharma's annual revenue?
China Pharma reported total revenue of $4.1 million for fiscal year 2025, which ended on December 31, 2025. That was down 8.5% from $4.5 million the previous year.
Is China Pharma profitable?
No. China Pharma reported a net loss of $3.2 million in fiscal 2025, a net profit margin of −76.9%; its operating margin was −74.5%.
What is China Pharma's gross margin?
China Pharma's gross margin was −3.2% in fiscal 2025: for every $100 of revenue, China Pharma kept $-3 after the direct cost of its products and services.
How much does China Pharma spend on research and development?
China Pharma spent $0.3 million on research and development in fiscal 2025, 6.8% of revenue.
How fast is China Pharma growing?
Revenue grew −17.5% a year on average over the last five fiscal years, from $10.9 million to $4.1 million.
What are China Pharma's earnings per share?
China Pharma earned $-0.21 per diluted share in fiscal 2025, compared with $-2.80 a year earlier.
When will China Pharma report its next earnings?
China Pharma is expected to report results for the quarter ending September 30, 2026 on November 11, 2026.
When does China Pharma's fiscal year end?
China Pharma's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on April 1, 2026.